Filtered By:
Vaccination: Shingles (Herpes Zoster) Vaccine
This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 2063 results found since Jan 2013.
What Causes Neck Stiffness?
Discussion
The complaint of neck stiffness always makes the clinician a little concerned until he/she understands the whole history because of the potential diagnosis of meningitis/encephalitis. While this potential is always concerning, there are many other causes of neck stiffness or pain to consider that are much more common. Normal wear and tear, injury or overuse that occur in daily activities and work can cause neck stiffness or pain. Often, even in adults, the cause of the pain is not recognized. Good examples are the adolescent above, or an innocent stumble, particularly if carrying something that may cause a perso...
Source: PediatricEducation.org - June 30, 2014 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news
Fight Aging! Newsletter, February 13th 2023
This study investigated whether taller Polish adults live longer than their shorter counterparts. Data on declared height were available from 848,860 individuals who died in the years 2004-2008 in Poland. To allow for the cohort effect, the Z-values were generated. Separately for both sexes, Pearson's r coefficients of correlation were calculated. Subsequently, one way ANOVA was performed.
The correlation between adult height and longevity was negative and statistically significant in both men and women. After eliminating the effects of secular trends in height, the correlation was very weak (r = -0.0044 in men and ...
Source: Fight Aging! - February 12, 2023 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Varicella Virus, the Old and the New
I want to reawaken awareness of a disappearing but highly contagious infectious disease — varicella. Thanks to immunizations for the wild-type varicella virus and shingles, or herpes zoster, younger health care providers are less aware of the appearance and clinical presentations of this viral infection.Presentations of this viral disease have markedly declined and presentations are often atypical since the advent of immunizations for varicella in 1995. This DNA virus within the herpes virus family is generally a mild childhood disease but can wreak physical havoc in adults, especially pregnant women. Immunosuppressed...
Source: M2E Too! Mellick's Multimedia EduBlog - February 1, 2017 Category: Emergency Medicine Tags: Blog Posts Source Type: blogs
Willingness to Vaccinate Against Herpes Zoster and Its Associated Factors Across WHO Regions: Global Systematic Review and Meta-Analysis
CONCLUSIONS: Only 1 in 2 individuals showed a willingness to be vaccinated against HZ. The willingness rate was the highest in the Eastern Mediterranean Region. Our findings show the critical role HCWs play in promoting HZ vaccination. Monitoring HZ vaccination willingness is necessary to inform public health decision-making. These findings provide critical insights for designing future life-course immunization programs.PMID:36892937 | DOI:10.2196/43893
Source: Herpes - March 9, 2023 Category: Infectious Diseases Authors: Qiang Wang Liuqing Yang Lan Li Chang Liu Hui Jin Leesa Lin Source Type: research
Will Governor Brown Take the Risk as the African-American Community Says NO to SB277?
Conclusion
Will Governor Jerry Brown think twice and really risk the wrath of the black community? Will he even read Mrs. Sullivan’s letter or care about the many religious groups opposing vaccinations due to their ingredients?
It appears that more governments worldwide are mandating vaccinations on a daily basis and parents are completely powerless to stop them. Who are these people who make all the decisions, and what right do they have to impose their largely unproven theories that ALL vaccinations are safe and effective for ALL children?
Let’s face it, it does make you wonder what their real agenda is, doesn’t it...
Source: vactruth.com - June 16, 2015 Category: Allergy & Immunology Authors: Christina England Tags: Christina England Logical Top Picks Mandatory Vaccination SB 277 vaccine mandate Source Type: blogs
New Clinical Trials Try Unorthodox Ways to Target Alzheimer ’ s
Alzheimer’s disease affects an estimated 5 million individuals in the US and causes a devastating loss of cognitive function due to the buildup of beta-amyloid and tau proteins in the brain. Previous efforts to combat this disease have focused on developing drugs that target beta-amyloid, but such treatments have been unsuccessful in patients so far. Several exciting new approaches for treating Alzheimer’s are currently being tested in clinical trials in the US and Europe. These trials will assess the efficacy of an anti-viral drug that is normally used to treat herpes, and a new vaccine that generates antibodies again...
Source: World of Psychology - May 20, 2017 Category: Psychiatry & Psychology Authors: Psych Central Staff Tags: Alzheimer's Brain Blogger Disorders Publishers Research Treatment Alzheimer's disease beta-amyloid Clinical Trials Cognitive Abilities Dementia herpes Hugo Lövheim microtubules neuronal axons Neurons tau proteins vaccine Source Type: blogs
Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Addressing racial inequality and its effects on vaccination rate: A trial comparing a pharmacist and peer educational program (MOTIVATE) in diverse older adults
CONCLUSIONS: Both interventions significantly improved knowledge and trust toward vaccination and retained their effect 1 month after the program. The 2 effective community-based education models should be expanded to ensure timely and trusted information is available to educate older adults about vaccine-preventable diseases. Further research is encouraged to assess the long-term cost-effectiveness of these models' utilization on a larger scale. DISCLOSURES: Dr Schafer is an employee of Merck; however, at the time of the project, he was a professor at Thomas Jefferson University. The other authors have no conflicts of int...
Source: Herpes - July 31, 2023 Category: Infectious Diseases Authors: Katherine M Prioli Ayse Akincigil Tarlan Namvar Jocelyn Mitchell-Williams Jason J Schafer Renee C Cunningham Lynn Fields-Harris Megan McCoy Ronald Vertsman Ashley Guesnier Laura T Pizzi Source Type: research
U.S. Will Have Enough COVID-19 Vaccines for All Adults by End of May, Biden Says
(WASHINGTON) — President Joe Biden said Tuesday that the U.S. expects to take delivery of enough coronavirus vaccines for all adult Americans by the end of May, two months earlier than anticipated, as his administration announced that drugmaker Merck & Co. will help produce rival Johnson & Johnson’s newly approved shot.
With the bolstered supply, Biden also announced he would be using the powers of the federal government to direct all states to prioritize vaccinating teachers, and said the federal government would provide the doses directly through its pharmacy program. He challenged states to administe...
Source: TIME: Health - March 2, 2021 Category: Consumer Health News Authors: ZEKE MILLER, LINDA A. JOHNSON and JONATHAN LEMIRE/AP Tags: Uncategorized COVID-19 wire Source Type: news
The Awareness and Attitude of Physicians to Older Adult Routine Vaccination Scheme
CONCLUSION: Awareness of routine vaccination schedules should be improved among health-care professionals, and reminders for immunization should be provided periodically in each health-care setting.PMID:36338873 | PMC:PMC9635550 | DOI:10.2147/CIA.S382311
Source: Herpes - November 7, 2022 Category: Infectious Diseases Authors: Esra Ates Bulut Suade Ozlem Badak Huseyin Aksoy Ayse Fadiloglu Ahmet Turan Isik Source Type: research
